DRMA [NASD]
Dermata Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.26 Insider Own1.40% Shs Outstand8.33M Perf Week0.69%
Market Cap5.75M Forward P/E- EPS next Y-1.41 Insider Trans0.00% Shs Float4.28M Perf Month-38.07%
Income-10.50M PEG- EPS next Q-0.40 Inst Own1.30% Short Float0.89% Perf Quarter-41.26%
Sales- P/S- EPS this Y-223.30% Inst Trans-20.47% Short Ratio0.32 Perf Half Y-84.87%
Book/sh1.21 P/B0.61 EPS next Y40.60% ROA-149.00% Target Price9.00 Perf Year-
Cash/sh1.39 P/C0.53 EPS next 5Y- ROE-183.70% 52W Range0.62 - 6.95 Perf YTD-57.47%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-89.01% Beta-
Dividend %- Quick Ratio7.70 Sales past 5Y- Gross Margin- 52W Low23.23% ATR0.14
Employees8 Current Ratio7.70 Sales Q/Q- Oper. Margin- RSI (14)35.87 Volatility28.68% 16.51%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.99 Prev Close0.74
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume118.03K Price0.76
Recom2.00 SMA20-20.59% SMA50-29.90% SMA200-72.00% Volume106,419 Change3.23%
May-16-22 04:05PM  
Apr-25-22 04:50PM  
Apr-21-22 09:00AM  
Mar-28-22 08:30AM  
Mar-24-22 08:30AM  
Feb-10-22 07:27AM  
Feb-07-22 08:58AM  
Jan-13-22 08:30AM  
Jan-05-22 08:30AM  
Nov-22-21 05:06AM  
04:53AM  
Nov-19-21 02:17PM  
08:30AM  
Nov-17-21 08:00AM  
Nov-15-21 04:01PM  
Nov-12-21 08:00AM  
Nov-11-21 06:00AM  
Oct-19-21 07:00AM  
06:53AM  
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.